NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions

References

• Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 2011;17:1040–1044.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012;136:25–31.
   PubMed Web of Science ®Google Scholar
• Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012;8:85–93.
   PubMed Web of Science ®Google Scholar
• Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 2012;7:e51458.
   Google Scholar
• Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013;38:1245–1252.
   PubMed Web of Science ®Google Scholar
• Said SI. Glutamate receptors and asthmatic airway disease. Trends Pharmacol Sci 1999;20:132–134.
   PubMed Web of Science ®Google Scholar
• Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE. A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann N Y Acad Sci 2000;921:115–118.
   PubMed Web of Science ®Google Scholar
• Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999;72:1283–1293.
   PubMed Web of Science ®Google Scholar
• Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001;276:708–714.
   PubMed Web of Science ®Google Scholar
• Zemlyak I, Furman S, Brenneman DE, Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 2000;96:39–43.
   PubMedGoogle Scholar
• Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 2001;296:57–63.
   PubMed Web of Science ®Google Scholar
• Ashur-Fabian O, Giladi E, Furman S, Steingart RA, Wollman Y, Fridkin M, et al. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci Lett 2001;307:167–170.
   PubMed Web of Science ®Google Scholar
• Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 2003;20:315–322.
   PubMed Web of Science ®Google Scholar
• Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002;33:1085–1092.
   PubMed Web of Science ®Google Scholar
• Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 2002;19:167–170.
   PubMed Web of Science ®Google Scholar
• Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004;361:128–131.
   PubMed Web of Science ®Google Scholar
• Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 2001;297:774–779.
   PubMed Web of Science ®Google Scholar
• Morimoto BH, Fox AW, Stewart AJ, Gold M. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol 2013;6:483–502.
   PubMed Web of Science ®Google Scholar
• Gozes I, Brenneman DE, Geppetti P, Kastin AJ, Mains RE, Moody TW, et al. Neuropeptides: brain messengers of many faces. Trends Neurosci 2001;24:687–690.
   PubMed Web of Science ®Google Scholar
• Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 2001;204:3161–3170.
   PubMed Web of Science ®Google Scholar
• Wilson MH, Newman S, Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009;8:175–191.
   PubMed Web of Science ®Google Scholar
• Bartsch P, Swenson ER. Acute high-altitude illnesses. N Engl J Med 2013;369:1666–1667.
   PubMed Web of Science ®Google Scholar
• Arya A, Sethy NK, Singh SK, Das M, Bhargava K. Cerium oxide nanoparticles protect rodent lungs from hypobaric hypoxia-induced oxidative stress and inflammation. Int J Nanomedicine 2013;8:4507–4520.
   PubMed Web of Science ®Google Scholar
• Sharma NK, Sethy NK, Meena RN, Ilavazhagan G, Das M, Bhargava K. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides 2011;32:1217–1224.
   PubMed Web of Science ®Google Scholar
• Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011;46:597–606.
   PubMed Web of Science ®Google Scholar
• Maiti P, Singh SB, Sharma AK, Muthuraju S, Banerjee PK, Ilavazhagan G. Hypobaric hypoxia induces oxidative stress in rat brain. Neurochem Int 2006;49:709–716.
   PubMed Web of Science ®Google Scholar
• Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500–508.
   PubMed Web of Science ®Google Scholar
• Witgen BM, Lifshitz J, Smith ML, Schwarzbach E, Liang SL, Grady MS, Cohen AS. Regional hippocampal alteration associated with cognitive deficit following experimental brain injury: a systems, network and cellular evaluation. Neuroscience 2005;133:1–15.
   PubMed Web of Science ®Google Scholar
• Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236–245.
   PubMed Web of Science ®Google Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007;323:438–449.
   PubMed Web of Science ®Google Scholar
• Sharma NK, Sethy NK, Bhargava K. Comparative proteome analysis reveals differential regulation of glycolytic and antioxidant enzymes in cortex and hippocampus exposed to short-term hypobaric hypoxia. J Proteomics 2013;79:277–298.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Tajima F, Nakamura A, Yagura S, Ookawara T, Yamashita H, et al. Effects of hypobaric hypoxia on antioxidant enzymes in rats. J Physiol 1995;489:869–876.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin K, Peel A, Mao XO, Xie L, Greenberg DA. Neuroglobin protects the brain from experimental stroke in vivo. Proc Natl Acad Sci U S A 2003;100:3497–3500.
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Dejda A, Niewiadomski P, Gozes I, Nowak JZ. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. J Mol Neurosci 2005;25:215–224.
   PubMed Web of Science ®Google Scholar